Skip to main content
TipRanks
Go Ultimate75% OFF

Implanet SA (ALIMP) AI Stock Analysis

3 Followers
FR:ALIMP

Implanet SA

(Paris:ALIMP)

Select Model
Rating:39Underperform
Price Target:EUR 0.13â–¼(-1.48% Downside)
Action:downgraded
Date:10/15/26

Implanet's very low score reflects critical fundamental and technical weaknesses. Although top-line revenue and gross margins are improving, a severe lack of profitability, heavy debt burden, and consistent cash burn present significant viability risks. These fundamental struggles are compounded by decidedly bearish price trends and a poor valuation profile driven by negative earnings.

Positive Factors
Revenue ReboundThe strong revenue rebound indicates improving demand for Implanet’s orthopedic and spine products and suggests greater commercial traction. If maintained, this expanding sales base can improve operating leverage, support investment in the product portfolio, and strengthen the company’s position with healthcare customers.
Negative Factors
Persistent LossesPersistent operating and net losses show that the current revenue scale and improved gross margin are not yet sufficient to cover the company’s broader cost base. Without a durable path to break-even, future growth may continue requiring financing and may not translate into retained earnings.

Implanet SA (ALIMP) vs. iShares MSCI France ETF (EWQ)

-40%-30%-20%-10%0%10%20%30%FR:ALIMP-36.62%EWQ-1.35%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 20.39M
Dividend Yield
―
Average Volume (3M)
58.13K
Price to Earnings (P/E)
-4.7
Beta (1Y)
-0.01
Revenue Growth
24.35%
EPS Growth
15.00%
Country
France
Employees
49
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Implanet SA Business Overview & Revenue Model

Company Description

Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. Its s...

How the Company Makes Money

Implanet generates revenue primarily from selling orthopedic and spine implant products and the associated surgical instruments/ancillaries required to perform procedures using its systems. Revenue is typically recognized through product sales to hos...

Implanet SA Financial Statement Overview

Summary

While the company shows promising revenue growth and expanding margins, financial health is severely compromised by a highly leveraged balance sheet, ongoing cash burn, and persistent unprofitability.

Income Statement

45Neutral

Balance Sheet

25Negative

Cash Flow

38Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue13.80M12.47M9.41M7.45M8.03M6.14M
Gross Profit8.08M5.93M4.10M3.13M3.91M2.74M
EBITDA-3.78M-2.91M-3.82M-5.08M-1.84M-2.70M
Net Income-4.42M-4.38M-4.37M-6.68M-3.54M-4.61M
Balance Sheet
Total Assets17.74M18.45M14.89M10.64M14.47M16.70M
Cash, Cash Equivalents and Short-Term Investments1.01M3.01M1.60M248.00K531.00K1.87M
Total Debt5.46M5.92M6.50M6.15M6.80M9.61M
Total Liabilities19.46M18.04M14.16M10.81M10.93M13.90M
Stockholders Equity-1.72M404.00K727.00K-174.00K3.54M2.80M
Cash Flow
Free Cash Flow-2.29M-2.15M-2.81M-2.17M-3.04M-3.91M
Operating Cash Flow-733.00K-589.00K-2.32M-1.45M-2.47M-3.52M
Investing Cash Flow-1.62M-1.56M-844.00K-768.00K-570.00K1.57M
Financing Cash Flow2.96M3.64M4.37M1.95M1.60M2.73M

Implanet SA Technical Analysis

Technical Analysis SentimentNegative
Last Price0.14

Price Trends

50DMA0.15Negative
100DMA0.17Negative
200DMA0.18Negative

Market Momentum

MACD-0.01Negative
RSI39.78Neutral
STOCH63.70Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIMP, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.14, below the 50-day MA of 0.15, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 39.78 is Neutral, neither overbought nor oversold. The STOCH value of 63.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALIMP.

Implanet SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALIMP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:CVXFR:CVX52NeutralEUR 290.60M-7.18-120.57%―-100.00%-72.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALTHEFR:ALTHE46NeutralEUR 43.09M-5.64453.10%―-16.98%20.31%
FR:ALMDTFR:ALMDT43NeutralEUR 205.84M-3.41271.64%―2.16%-5.26%
FR:ALMKTFR:ALMKT43NeutralEUR 17.30M1.40-157.72%―3.38%―
FR:ALIMPFR:ALIMP39UnderperformEUR 20.39M-4.70671.47%―24.35%15.00%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%FR:ALIMPFR:ALMKTFR:ALTHEFR:ALDMSFR:ALMDTFR:CVXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALIMP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALIMPImplanet SA0.14-0.08-36.62%
FR:ALMKTMAUNA KEA TECHNOLOGIES0.090.0111.25%
FR:ALTHETheraclion SA0.57-0.07-11.15%
FR:ALDMSDiagnostic Medical Systems0.90-0.32-26.39%
FR:ALMDTMedian Technologies4.241.4953.90%
FR:CVXAffluent Medical SA4.523.00197.37%

Implanet SA Corporate Events

Implanet extends growth streak on spine implants and U.S. surge

Oct 13, 2026

Implanet reported its ninth consecutive quarter of growth, with third-quarter 2026 revenue up 18% to €3.44 million and nine‑month revenue rising 21% to €10.57 million, driven by strong demand for spine implants and SMTP medical equipment. The United...

Implanet lifts H1 revenue 23% as Jazz Spinal System drives margin gains

Sep 15, 2026

Implanet reported first-half 2026 revenue of €7.1 million, up 23% year-on-year, with growth driven by its spine implants business and the strong performance of the new Jazz Spinal System hybrid posterior fixation solution. Sales of the SMTP ultrasoni...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026